Fresenius Narrows 2026 Operating Income Outlook to Lower Half of Range
Key Facts
Fresenius Medical Care narrowed its 2026 operating income outlook, saying it expects performance to range from flat to a mid-single-digit percentage decline, with the forecast now pointing to the lower half of the previous range. The announcement came in its third-quarter results statement issued on November 3, 2026. In the second quarter, the company had maintained a range from mid-single-digit positive growth to a mid-single-digit decline, while expecting revenue to be broadly stable. The revision means annual revenue is still expected to be near the prior year's level, while operating income estimates have become more cautious. Chief Executive Shervin Korangy said that, three weeks into the role, he sees many parts of the company as still being at an early stage of development after structural changes in recent years.
In the third quarter, reported revenue rose 1% to 4,937 million euros, but fell 1% on a constant-currency basis, while organic growth was 0.1%. Adjusted operating income before special items, meanwhile, fell 5% to 545 million euros, or 6% on a constant-currency basis. The adjusted operating income margin declined to 11.0% from 11.7% in the same period of 2025. The comparison reveals a gap between nearly stable revenue and weaker operating profitability, explaining why the revision focused on the operating income outlook. The company said underlying performance improvements were partly offset by the expected negative effects of TDAPA rules and rising inflationary pressure.
At the business level, Care Delivery and Care Enablement supported the group's organic revenue, while Value-Based Care posted an expected decline. The chief financial officer said underlying operating income in Care Delivery improved 21% after excluding the negative impact of TDAPA rules. Regulatory and inflationary pressures, however, limited the extent to which underlying operational improvement fed through to the consolidated result, the company said. Reuters reported that treatments in the U.S. market fell 1.1% in the third quarter, after declines of 0.4% in the first quarter and 0.9% in the second quarter. This trend places the decline in U.S. treatments among the operating factors accompanying the quarterly results, without changing the company's expectation for broadly stable 2026 revenue.
Reported operating income fell 19% and reported net income fell 42% in the third quarter, with the company attributing the decline mainly to one-off costs tied to refining its China strategy. These costs amounted to 108 million euros, most of them from impairment losses, depreciation and costs of exiting activities. These items distinguish the decline in reported results from adjusted operating income performance, which fell 5% under the company's measure excluding special items. Operating cash flow, meanwhile, rose 8% to 798 million euros in the quarter. In the first nine months of 2026, operating cash flow increased 12% to 1,885 million euros, and the company said the improvement in both periods was mainly linked to working capital developments.
In the second quarter, the company said 2026 revenue was expected to be broadly stable and operating income to remain at a level consistent with the prior year, within a range from positive growth to a mid-single-digit decline. In its third-quarter statement, Korangy said: "Three weeks into my role as CEO, I am excited about the opportunities ahead. Following the structural changes of recent years, many parts of our business are still at an early stage of development." The narrowing of the range to its lower half follows the first nine months' results, as the company seeks to continue its FME25+ transformation program. It expects savings of 250 million euros in 2026, alongside one-off program costs of 350 million euros. Total targeted savings are expected to reach 1.2 billion euros by the end of 2027.
The company said the rollout of the 5008X CAREsystem in the U.S. was on track; it was available at 348 clinics, where 1.3 million treatment sessions had been conducted by the results announcement. The company is scheduled to hold a call for analysts and investors on its third-quarter results on November 3, 2026, at 2:00 p.m. Central European Time. FSNUY shares closed at $13.56 in the November 2 session, according to EL7 data. The information provided did not include a verified price for the following session or share movement after the results were released. The scheduled call gives the company an opportunity to present details of its performance and revised outlook to investors on results day.